Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial
This study evaluated the efficacy and safety ...
Source: BMC Medicine - Category: Internal Medicine Authors: Li Xu, Jinzhang Chen, Chang Liu, Xiaoling Song, Yanqiao Zhang, Haitao Zhao, Sheng Yan, Weidong Jia, Zheng Wu, Yabing Guo, Jiayin Yang, Wei Gong, Yue Ma, Xiaobo Yang, Zhenzhen Gao, Nu Zhang & hellip; Tags: Research article Source Type: research
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Immunotherapy | Internal Medicine | Liver Cancer | Study